Business Description

Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Name Current Vs Industry Vs History
Cash-To-Debt 0.14
Equity-to-Asset 0.55
Debt-to-Equity 0.5
Debt-to-EBITDA 3.6
Interest Coverage 7.42
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.05
Distress
Grey
Safe
Beneish M-Score -2.31
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 30.8
9-Day RSI 23.84
14-Day RSI 24.7

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2
Quick Ratio 1.26
Cash Ratio 0.31
Days Inventory 272.84
Days Sales Outstanding 78.66
Days Payable 65.45

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio 1.7
Shareholder Yield % 0.12

Financials (Next Earnings Date:2024-04-25 Est.)

MIL:1BIIB's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Biogen Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 9,126.458
EPS (TTM) (€) 7.379
Beta 0
Volatility % 0
14-Day RSI 24.7
14-Day ATR (€) 1.747026
20-Day SMA (€) 195.515
12-1 Month Momentum % 0
52-Week Range (€) 184.4 - 244.6
Shares Outstanding (Mil) 145.36

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biogen Inc Filings

Filing Date Document Date Form
No Filing Data

Biogen Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Biogen Inc Frequently Asked Questions

What is Biogen Inc(MIL:1BIIB)'s stock price today?
The current price of MIL:1BIIB is €185.85. The 52 week high of MIL:1BIIB is €244.60 and 52 week low is €184.40.
When is next earnings date of Biogen Inc(MIL:1BIIB)?
The next earnings date of Biogen Inc(MIL:1BIIB) is 2024-04-25 Est..
Does Biogen Inc(MIL:1BIIB) pay dividends? If so, how much?
Biogen Inc(MIL:1BIIB) does not pay dividend.

Press Release

Subject Date
No Press Release